- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
eMed Technologies will refile IPO
Teleradiology and miniPACS provider eMed Technologies (formerly Access Radiology) has decided that the stock market is being friendlier to Internet and healthcare companies and plans to refile its initial public offering with the Securities and Exchange
Teleradiology and miniPACS provider eMed Technologies (formerly Access Radiology) has decided that the stock market is being friendlier to Internet and healthcare companies and plans to refile its initial public offering with the Securities and Exchange Commission. The Lexington, MA-based company pulled its IPO in November just as it was preparing to issue, citing a volatile market and investor apprehension about healthcare information systems vendors (SCAN 10/27/99).
eMed had hoped to raise more than $57 million through the IPO by selling 3.1 million shares at $12 to $14/share. The company anticipates the new IPO will be issued sometime during the first quarter of 2000, according to John Strauss, vice president of marketing. eMed also plans to use a different underwriter for this offering.
eMed is actively pursuing an Internet-based strategy that includes a new Web service for radiologists (eMed.net), and an extended relationship with compression software developer Aware to develop and market Web-based imaging products.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
